The U.S. Food and Drug Administration has approved the SetPoint System, a neuroimmune modulation device for the treatment of adults living with moderate-to-severe rheumatoid arthritis (RA). The ...
Credit: SetPoint Medical. The SetPoint System consists of a neurostimulation device that is surgically placed under general anesthesia on the vagus nerve. In a phase 3 study, the SetPoint neuroimmune ...
VALENCIA, Calif.--(BUSINESS WIRE)--SetPoint Medical, a company dedicated to developing therapies for people living with chronic autoimmune diseases, today announced that the U.S. Food and Drug ...
In a phase 3 study, the SetPoint neuroimmune modulation device was found to be an effective treatment for patients with difficult-to-treat RA. The Food and Drug Administration (FDA) has approved the ...
Many developmental and regenerative processes require coordinated modulation of the immune response alongside the rapid formation of functional blood vessels. Wound healing, liver regeneration, ...
Camrelizumab Plus Famitinib versus Camrelizumab Alone and Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer: A Randomized, Phase II Study The interplay between the human ...
ABSTRACT: This study introduces a Hybrid Bimodal Model for Analog-to-Digital (ADC) and Digital-to-Analog (DAC) signal conversions, addressing limitations of traditional systems, such as inefficiencies ...
Abstract: A novel signal quantization scheme based on adaptive differential pulse code modulation (ADPCM) is proposed and experimentally demonstrated. By adaptively adjusting the quantization step ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback